Alaunos Therapeutics is:

• Like an early-stage Kite Pharma (acquired by Gilead), but specializing in TCR-engineered T-cell therapies for cancer.
• A clinical-stage biotech similar to a young Moderna, but dedicated to developing platform-based T-cell therapies for oncology.

• TCR Library: A set of T-cell receptors in Phase I/II clinical trials targeting mutated KRAS, TP53, and EGFR for various solid tumors.
• hunTR: A human neoantigen T-cell receptor platform designed to identify and develop novel T-cell therapies.
• mbIL-15: A therapeutic agent under development for the treatment of solid tumors.

Alaunos Therapeutics (TCRT) is a clinical-stage oncology-focused cell therapy company. Based on the provided description, the company is primarily engaged in the research and development of adoptive TCR engineered T-cell therapies, with its lead programs currently in Phase I/II clinical trials.

As a clinical-stage company, Alaunos Therapeutics is not yet commercializing its therapies. Therefore, it does not currently have major customers that purchase its products or services.

• WuXi AppTec Co., Ltd. (2359.HK)

Holger Weis, Chief Executive Officer

Mr. Weis was appointed Chief Executive Officer of Alaunos Therapeutics, effective July 2, 2025. He has served as a member of the company's Board of Directors since December 2020 and previously held the position of Chairman of the Board. Prior to his CEO appointment, Mr. Weis founded Weis Advisors, Inc., a consulting firm for life science companies, in April 2018, where he served as principal. His extensive experience in the life sciences and finance sectors includes leadership roles at DemeRx, Inc., a clinical-stage pharmaceutical company, where he served as Chief Operating Officer, Chief Financial Officer, and President. He also held the position of Chief Financial Officer and Director at PhenoTarget Biosciences, Inc., a biotech start-up. Earlier in his career, Mr. Weis served as Vice President & Chief Financial Officer, Secretary, and Treasurer of NovaVision, Inc., and as Chief Financial Officer & Treasurer of GMP Companies, Inc., a developer of pharmaceutical, medical device, and diagnostic technologies. He began his career as a Senior Manager at Ernst & Young.

Ferdinand Groenewald, Vice President, Finance and Principal Accounting Officer

Mr. Groenewald was appointed Vice President, Finance and Principal Accounting Officer of Alaunos Therapeutics in February 2024 (and listed as VP, Finance in February 2025). Since July 2023, he has served in various capacities at CFO Squad, a firm offering outsourced accounting and consulting services. His prior experience includes serving as Chief Accounting Officer of Muscle Maker, Inc., a Nasdaq-listed company, from January 2023 to July 2023, and as Chief Financial Officer of the same company from September 2018 to January 2023. He also held roles as Vice President of Finance, Principal Financial Officer, and Principal Accounting Officer for Muscle Maker, Inc. and its subsidiaries. Earlier in his career, he worked as a Senior Financial Accounting Consultant at Pharos Advisors, Inc. and a Senior Staff Accountant at Financial Consulting Strategies, LLC.

Raffaele Baffa, M.D., Ph.D., Chief Medical Officer

Dr. Baffa joined Ziopharm (now Alaunos Therapeutics) as Chief Medical Officer in November 2020. Before joining Alaunos, he was the Head of Research & Development and Chief Medical Officer for Medisix, an immune engineering company focused on novel cellular therapies for T-cell malignancies. He previously served as Vice President and Therapeutic Area Head of Oncology, Global Clinical Development for Shire, and subsequently as Chief Medical Officer of Servier Pharmaceuticals after the acquisition of Shire's oncology division. Dr. Baffa has also held leadership positions at prominent pharmaceutical companies such as Pfizer and Sanofi. He earned his M.D. from the University of Padova and a Ph.D. from the University of Parma, both in Italy.

The key risks to Alaunos Therapeutics (TCRT) primarily revolve around its financial viability, the inherent uncertainties of clinical development and regulatory approval, and the protection of its intellectual property in a competitive landscape.

The most significant risk to Alaunos Therapeutics is its **financial viability and ability to continue as a going concern**. The company has consistently reported negative net income and operating cash flow, indicating it is "quickly burning through cash". Its Altman-Z score places it in a "distress zone," suggesting a risk of bankruptcy. While Alaunos Therapeutics maintains a healthy current ratio and holds more cash than debt, these factors are offset by its substantial operating losses and the ongoing need for additional funding to sustain its costly clinical trials. There is also a risk of potential delisting from the Nasdaq Capital Market if its stockholder equity falls below required thresholds.

Another major risk stems from the **uncertainties of clinical trial success and regulatory approval**. As a clinical-stage oncology-focused cell therapy company, the future of Alaunos Therapeutics depends heavily on whether its product candidates, such as the TCR Library and hunTR platform, successfully advance through preclinical research and clinical trials. There is no guarantee that these candidates will receive clearance from regulatory agencies like the U.S. Food and Drug Administration (FDA) or obtain final marketing approval for their intended indications. Failures or delays in clinical development would severely impact the company's prospects.

Finally, **intellectual property protection and intense competition** represent a key risk. Alaunos Therapeutics relies on its proprietary TCR library and platforms. The strength and enforceability of its intellectual property rights are crucial for its business model. The oncology cell therapy market is highly competitive, and the company faces significant competition from other pharmaceutical and biotechnology companies developing similar or alternative treatments. The company recently ended a licensing agreement with Precigen, Inc., and is now focusing on securing intellectual property protection for its TCRs, which underscores the importance of this area.

Alaunos Therapeutics (TCRT) operates in the clinical-stage oncology sector, focusing on adoptive T-cell receptor (TCR) engineered T-cell therapies for various solid tumors. The company's main products, including its TCR Library, hunTR platform, and mbIL-15, target a range of cancers.

The addressable markets for Alaunos Therapeutics' target indications are substantial, driven by the high incidence and unmet medical needs in these cancer types. Below are the estimated market sizes for the primary cancers the company's therapies aim to address, along with the broader TCR therapy market:

Non-Small Cell Lung Cancer (NSCLC)

The global non-small cell lung cancer market is estimated to be valued at USD 28.61 billion in 2025 and is projected to reach USD 54.38 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.6% from 2025 to 2032. Another report indicates the global market size at USD 22.1 billion in 2025, with a projection to reach USD 53.9 billion by 2034 at a CAGR of 10.4%. North America is a significant region, expected to hold a 38.7% share of the global market in 2025. The U.S. non-small cell lung cancer market alone was valued at USD 8.2 billion in 2024.

Colorectal Cancer

The global colorectal cancer therapeutics market is estimated to be valued at USD 13.74 billion in 2025 and is expected to reach USD 19.08 billion by 2032, exhibiting a CAGR of 4.8% from 2025 to 2032. Another source projects the global market at USD 12.79 billion in 2024, growing to USD 19.95 billion by 2034 with a CAGR of 4.55%. North America is a dominant region, holding a 39.5% market share in 2025. The U.S. colorectal cancer therapeutics market was estimated at USD 3.42 billion in 2024 and is predicted to reach approximately USD 5.43 billion by 2034.

Endometrial Cancer

The global endometrial cancer market size is calculated at USD 31.09 billion in 2025 and is expected to reach approximately USD 51.15 billion by 2034, expanding at a CAGR of 5.69% from 2025 to 2034. The global endometrial cancer treatment market is projected to grow from USD 32.0 billion in 2025 to USD 53.7 billion by 2035 at a CAGR of 5.3%. North America accounted for over 41% of the market share in 2024. The U.S. endometrial cancer treatment market is estimated to be valued at USD 11.3 billion in 2025.

Pancreatic Cancer

The global pancreatic cancer market size is calculated at USD 3.25 billion in 2025 and is projected to surpass around USD 10.25 billion by 2034, growing at a CAGR of 13.62% from 2025 to 2034. Another report estimates the global market at USD 3.01 billion in 2025, reaching USD 9.57 billion by 2034 with a CAGR of 13.7%. North America held the largest share in this market in 2024. The U.S. is the dominant region within North America, accounting for 89.00% of the share in 2023.

Ovarian Cancer

The global ovarian cancer market size reached USD 2.5 billion in 2025 and is expected to reach USD 5.8 billion by 2034, exhibiting a CAGR of 9.21% during 2026-2034. Another estimate places the global market size at USD 3.5 billion in 2023, projected to reach approximately USD 6.5 billion by 2032 with a CAGR of 7.2% from 2024 to 2032. North America holds a dominant position in the ovarian cancer market, accounting for over 40% of the global market share in 2023. The U.S. accounted for the largest market size of ovarian cancer in the 7MM (United States, EU4, UK, and Japan), with nearly USD 1,922 million in 2024.

Bile Duct Cancer (Cholangiocarcinoma)

The global bile duct cancer market size was valued at USD 3.6 billion in 2023 and is expected to expand at a CAGR of 8.5% between 2024 and 2032, reaching USD 7.4 billion by 2032. North America is a leading region in this market, expected to secure a 41.4% share by 2035.

TCR Therapy Market (Overall)

The global TCR therapy market size is estimated at USD 362 million in 2024, growing to USD 410.6 million in 2025, and is projected to reach around USD 1264.73 million by 2034, expanding at a CAGR of 13.44% between 2025 and 2034. Another source values the TCR therapy market at USD 442 million in 2025, projected to reach USD 1,563 million by 2035 with a 12.7% CAGR. The engineered TCR (T-cell Receptor) therapy market is driven by its solid tumor applications. North America dominated the TCR therapy market in 2024 with approximately 45% of the revenue share.

Alaunos Therapeutics (Nasdaq: TCRT) is strategically reprioritizing its focus, with expected revenue growth over the next 2-3 years primarily driven by a shift from its former TCR-T Library clinical programs towards its hunTR® TCR discovery platform and a novel small molecule oral obesity program, alongside potential broader strategic transactions.

1. Strategic Partnerships or Out-licensing of the hunTR® TCR Discovery Platform: Alaunos Therapeutics has announced its intention to refocus resources on its hunTR® TCR discovery platform and explore potential partnering opportunities. The hunTR® platform is designed for the rapid identification and functional validation of proprietary T-cell receptors (TCRs). Successful partnerships or out-licensing agreements for this platform could generate revenue through upfront payments, research funding, and future milestone or royalty payments from collaborators.
2. Advancement and Potential Commercialization or Strategic Partnership of the Small Molecule Oral Obesity Program (ALN1003): The company has redirected its primary drug development focus to an internal small molecule oral obesity program, ALN1003. Positive preclinical data has been reported for ALN1003, demonstrating dose-dependent weight loss and favorable changes in metabolic parameters in mouse studies. The company intends to initiate Investigational New Drug (IND)-enabling activities for ALN1003. Future revenue growth would stem from potential licensing agreements, milestone payments from partners, or eventual product sales if the program successfully progresses through clinical development and gains regulatory approval.
3. Completion of Strategic Alternatives, Including Acquisition, Merger, or Asset Sale: Alaunos Therapeutics is actively exploring broad strategic alternatives for the company, which may include an acquisition, merger, reverse merger, sale of assets, or other transactions. Such a transaction could provide a significant capital infusion or lead to the establishment of new revenue streams, such as royalties or milestone payments from the sale of specific assets, thereby driving future revenue growth for the company or its shareholders.

Share Repurchases

• A treasury stock buyback program was authorized by the Board of Directors in October 2020 to repurchase up to 500,000 shares of common stock, with no expiration date.
• As of March 31, 2021, 434,622 shares remained available for repurchase under the program.
• The company repurchased 31,256 shares during the three-month period ended March 31, 2021.

Share Issuance

• In November 2022, Alaunos Therapeutics priced a public offering of approximately 24.2 million shares of common stock for gross proceeds of about $15.7 million, intended to fund pipeline development, working capital, capital expenditures, and general corporate purposes.
• The company announced a registered direct offering in June 2025, which involved the purchase and sale of 610,399 shares of common stock (or pre-funded warrants) for gross proceeds of approximately $2.0 million, with net proceeds of about $1.9 million designated for its obesity program and general corporate purposes.
• Alaunos Therapeutics completed two private placements of preferred stock in 2025, raising $500,000 in April from Watermill Asset Management for Series A-1 Convertible Preferred Stock and $850,000 in June from other purchasers for Series A-2 Convertible Preferred Stock.

Inbound Investments

• In February 2026, a group of investors led by Adrian Price proposed a $7,000,000 private placement investment in equity or equity-linked securities, with the potential to result in a change of control of the company if completed.
• PMGC Capital LLC announced in May 2025 a planned Schedule 13D filing to disclose a 5.09% ownership stake in Alaunos Therapeutics, comprising 83,500 shares, reflecting a belief that the company is undervalued and has significant potential for shareholder value creation.

Capital Expenditures

• Proceeds from the November 2022 public offering, totaling $15.7 million, were intended to be used for capital expenditures, among other corporate purposes.
• Alaunos Therapeutics reported $0 in capital expenditures in Q3 2024.
• The company was investing in its own manufacturing capabilities with a commitment to making internal facilities operational in the first half of 2022 to support patient dosing for its TCR-T Library clinical trial.